{
  "guideline": {
    "id": "PA166328732",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Mavacamten - CYP2C19",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328732",
    "relatedChemicals": [
      {
        "id": "PA166272922",
        "name": "mavacamten",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166315343",
      "name": "Recommendation Annotation PA166315343",
      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166272922",
          "name": "mavacamten",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246222,
        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315341",
      "name": "Recommendation Annotation PA166315341",
      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166272922",
          "name": "mavacamten",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246220,
        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315344",
      "name": "Recommendation Annotation PA166315344",
      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166272922",
          "name": "mavacamten",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246223,
        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315342",
      "name": "Recommendation Annotation PA166315342",
      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166272922",
          "name": "mavacamten",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246221,
        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}